NIH's Zika Vaccine Faces Funding Challenge After Skipping Industry Partnership
Agency wanted to move fast, but is now scrambling to pay for Phases I and II trials.
You may also be interested in...
Nothing's even in Phase II yet, but sponsors and US government researchers remain optimistic.
FDA and NIH officials propose three strategies for clinical trials, saying it will be challenging to identify the most promising candidates; Sanofi and Walter Reed researchers note challenges in vaccine development, including manufacturing scale up.
FDA, NIH officials urge permanent 'emergency defense fund' for public health as Zika and 21st Century Cures bills stall on Capitol Hill.